CONTRIBUTION OF HOST-DERIVED GROWTH-FACTORS TO IN-VIVO GROWTH OF A TRANSPLANTABLE MURINE MAMMARY-CARCINOMA

被引:20
作者
DAVIES, DE
FARMER, S
WHITE, J
SENIOR, PV
WARNES, SL
ALEXANDER, P
机构
[1] CRC Medical Oncology Unit, CF99, Southanpton General Hospital, Southanpton, S09 4XY, Tremona Road
关键词
D O I
10.1038/bjc.1994.290
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The contribution of host-derived growth factors to tumour growth in vivo was studied using the transplantable murine mammary carcinoma, MT1, grown in syngeneic mice. Promotion of growth of the mammary carcinoma by a factor(s) from the host was evident in experiments in which the carcinoma cells were inoculated intraperitoneally. In this environment, tumours develop as multiple solid nodules, each probably arising from an individual cell or a small cluster of cells. Tumour growth was found to occur in the peritoneal cavity following inoculation of 10(3) cells, but an inoculum of as few as ten cells grew if a leucocyte-rich exudate had first been induced. To determine which host-derived growth factors might contribute to growth of MTI, extracts of the tumour were first examined for growth factor activity. Fractionation of tumour extracts by either ion-exchange chromatography or gel filtration revealed several peaks of mitogenic activity, but none of this could be attributed to epidermal growth factor (EGF). Accordingly, an anti-EGF antibody was tested as a putative inhibitor of tumour growth as any effect of this antibody could be ascribed to removal of EGF derived from the host. The antibody was found to have potent anti-tumour activity when tested against MT1 tumours that had been inoculated into the peritoneal cavity. In contrast, the antibody had little effect on growth of the discrete tumour mass which formed when MTI was transplanted subcutaneously. The results suggest that host-derived EGF contributes to establishment of microcolonies of MT1 carcinoma within the peritoneal cavity. This may be directly, by providing growth factors to supplement those produced by the tumour until it reaches a certain critical mass to sustain autocrine growth, or indirectly, by affecting the production of other growth-stimulatory factors or cytokines.
引用
收藏
页码:263 / 269
页数:7
相关论文
共 26 条
[1]  
ALEXANDER P, 1987, BIOL CARCINOGENESIS, P191
[3]   ANTITUMOR EFFECTS OF DOXORUBICIN IN COMBINATION WITH ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODIES [J].
BASELGA, J ;
NORTON, L ;
MASUI, H ;
PANDIELLA, A ;
COPLAN, K ;
MILLER, WH ;
MENDELSOHN, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (16) :1327-1333
[4]  
BLACKLER J, 1988, BRIT J CANCER, V57, P223
[5]  
BREILLOUT F, 1989, J NATL CANCER I, V81, P703
[6]   HUMAN EPIDERMAL GROWTH-FACTOR AND PROLIFERATION OF HUMAN FIBROBLASTS [J].
CARPENTER, G ;
COHEN, S .
JOURNAL OF CELLULAR PHYSIOLOGY, 1976, 88 (02) :227-237
[7]   PHASE-I AND IMAGING TRIAL OF INDIUM-111-LABELED ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODY 225 IN PATIENTS WITH SQUAMOUS-CELL LUNG-CARCINOMA [J].
DIVGI, CR ;
WELT, S ;
KRIS, M ;
REAL, FX ;
YEH, SDJ ;
GRALLA, R ;
MERCHANT, B ;
SCHWEIGHART, S ;
UNGER, M ;
LARSON, SM ;
MENDELSOHN, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (02) :97-104
[8]   EPIDERMAL GROWTH-FACTOR STIMULATES THE GROWTH OF A431 TUMORS IN ATHYMIC MICE [J].
GINSBURG, E ;
VONDERHAAR, BK .
CANCER LETTERS, 1985, 28 (02) :143-150
[9]   A HEPARIN-BINDING GROWTH-FACTOR SECRETED BY MACROPHAGE-LIKE CELLS THAT IS RELATED TO EGF [J].
HIGASHIYAMA, S ;
ABRAHAM, JA ;
MILLER, J ;
FIDDES, JC ;
KLAGSBRUN, M .
SCIENCE, 1991, 251 (4996) :936-939
[10]   RELEASE OF DIFFERENT FRACTIONS OF EPIDERMAL GROWTH-FACTOR FROM HUMAN PLATELETS INVITRO - PREFERENTIAL RELEASE OF 140-KDA FRACTION [J].
HWANG, DL ;
LEVRAN, A ;
YEN, CF ;
SNIECINSKI, I .
REGULATORY PEPTIDES, 1992, 37 (02) :95-100